Paladin Advisory Group’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$16.8K Hold
400
0.01% 198
2026
Q1
$10.6K Hold
400
0.01% 204
2025
Q4
$11.6K Hold
400
0.01% 204
2025
Q3
$11.1K Hold
400
0.01% 198
2025
Q2
$9.74K Hold
400
0.01% 199
2025
Q1
$8.3K Hold
400
0.01% 201
2024
Q4
$9.42K Hold
400
0.01% 202
2024
Q3
$10.2K Hold
400
0.01% 199
2024
Q2
$9.29K Hold
400
0.01% 194
2024
Q1
$11.3K Hold
400
0.01% 190
2023
Q4
$13.1K Hold
400
0.01% 189
2023
Q3
$11.1K Hold
400
0.01% 208
2023
Q2
$13.6K Hold
400
0.01% 207
2023
Q1
$12K Buy
+400
New +$12.4K 0.01% 210
2022
Q2
Sell
-400
Closed -$14K 300
2022
Q1
$19K Buy
+400
New +$19.1K 0.02% 213

Other funds holding ARKG

Paladin Advisory Group's ARKG Position: Q2 2026 in Review

Paladin Advisory Group held its ARK Genomic Revolution ETF (ARKG) position steady in Q2 2026 at 400 shares worth $16.8K. The position accounts for 0.01% of the portfolio, ranked #198.

Paladin Advisory Group first reported a position in ARKG in Q1 2022 and has held it in 15 quarters since. The position peaked at $19K in Q1 2022. 103 funds tracked by Wall St. Rank hold ARKG as of Q2 2026.

  • Paladin Advisory Group held 400 shares of ARK Genomic Revolution ETF worth $16.8K as of Q2 2026.
  • Paladin Advisory Group left its ARK Genomic Revolution ETF share count unchanged in Q2 2026.
  • ARK Genomic Revolution ETF made up 0.01% of Paladin Advisory Group's portfolio in Q2 2026, its #198 holding.
  • Paladin Advisory Group first reported a position in ARK Genomic Revolution ETF in Q1 2022 and has held it in 15 quarters since.
  • Paladin Advisory Group's ARK Genomic Revolution ETF position peaked at $19K in Q1 2022.
  • 103 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2026.

Based on Paladin Advisory Group's 13F filing for Q2 2026, filed 28 Jul 2026.